Literature DB >> 26799242

High diagnostic accuracy of core needle biopsy of soft tissue tumors: An institutional experience.

Shanna M Colletti1, Ghassan A Tranesh1, Chantel R Whetsell1, Larissa N Chambers1, Aziza Nassar1.   

Abstract

BACKGROUND: Core needle biopsy (CNB) has been suboptimal in the subclassification and grading of mesenchymal tumors. Recent advances in molecular diagnostics have shown promise in improving this area. The institutional experience with CNBs of soft tissue lesions on cytology cases and correlated histologic follow-up has been evaluated. It also addressed the advantageous use of ancillary techniques, including immunohistochemistry and molecular studies.
METHODS: Archived cytologic CNB material and reports of patients with soft tissue lesions were retrieved and CNB results with final resection results were compared. Cases were re-reviewed and data were analyzed with descriptive statistics.
RESULTS: From archived data, 215 cases were extracted of 99 female and 116 male patients (mean [range] age, 59.9 [12-95] years). Categories were malignant (n = 157), suspicious (n = 16), and benign (n = 42). In total, 161 (74.9%) had subsequent surgical resection-130 were malignant; 8, suspicious; and 23, benign. Of the malignant or suspicious cases, 138 had follow-up histologic resections, with 97.9% concordance. The most common malignant tumor was liposarcoma (n = 41; 29.7%), followed by undifferentiated pleomorphic sarcoma (30; 21.7%). Of benign tumors, 23 (54.8%) had follow-up surgical resection. Low-grade gastrointestinal stromal tumor was the most common benign tumor (26.1%), followed by fibromatosis (21.7%). Cytohistologic correlation for all categories showed 96.9% concordance. Molecular ancillary studies correctly classified malignant tumors in 37 (26.8%) of the 138 cases.
CONCLUSION: CNB is a reliable modality for evaluating soft tissue neoplasms, with high histologic concordance rate.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  ancillary techniques; core needle biopsy; diagnosis; neoplasms; sarcoma; soft tissue

Mesh:

Year:  2016        PMID: 26799242     DOI: 10.1002/dc.23440

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  6 in total

Review 1.  Diagnosis and Management of Subcutaneous Soft Tissue Sarcoma.

Authors:  Makoto Endo; Nokitaka Setsu; Toshifumi Fujiwara; Takeaki Ishii; Makoto Nakagawa; Kenichiro Yahiro; Atsushi Kimura; Eijiro Shimada; Yasuharu Nakashima; Yoshihiro Matsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

Review 2.  Percutaneous biopsy of musculoskeletal tumors and the potential for needle tract seeding: technical considerations, current controversies, and outcomes.

Authors:  Cara Lai; Jeremiah R Long; Brandon T Larsen; Jose M Iturregui; Benjamin K Wilke; Krista A Goulding
Journal:  Skeletal Radiol       Date:  2022-10-18       Impact factor: 2.128

3.  Metastatic prostatic stromal sarcoma: A challenging diagnosis on fine-needle aspiration with broad differential diagnosis.

Authors:  Muhammad Siddique Khurram; Ghassan Tranesh; Ramen Sakhi; Ameer Hamza; Warda Ibrar; Roohi Bano
Journal:  Cytojournal       Date:  2017-06-20       Impact factor: 2.091

Review 4.  A meta-analysis supports core needle biopsy by radiologists for better histological diagnosis in soft tissue and bone sarcomas.

Authors:  Tadahiko Kubo; Taisuke Furuta; Muhammad P Johan; Tomohiko Sakuda; Mitsuo Ochi; Nobuo Adachi
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

5.  Nomogram Based on Ultrasonography and Clinical Features for Predicting Malignancy in Soft Tissue Tumors.

Authors:  Mengjie Wu; Yu Hu; Anjing Ren; Xiaojing Peng; Qian Ma; Cuilian Mao; Jing Hang; Ao Li
Journal:  Cancer Manag Res       Date:  2021-03-02       Impact factor: 3.989

6.  Comparative Study of Imprint Cytology and Histopathology of Soft Tissue Tumors.

Authors:  Sujit Kumar Dutta; Senjuti Dasgupta; Nirmal Kumar Bhattacharyya; Parul Jain; Debdas Bose; Pranab Kumar Biswas
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.